Organogenesis Holdings

ORGO

Market cap $515M

LOS ANGELES--(BUSINESS WIRE)--Organogenesis Holdings Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ORGO.

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis" or the "Company") (NASDAQ: ORGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th.

ORGO's AWC declined YoY, which is a significant headwind as it comprises the majority of its sales. However, the decline was mostly due to a delayed Medicare LCD, pressuring demand and product mix. Fortunately, the new LCD is a policy tailwind now. ORGO's Dermagraft and TransCyte reintroductions, plus FortiShield launch, also bode well for future growth in 2026.

Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with knee osteoarthritis (OA).

Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpoint Statistically significant maintenance of function (p

CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants David C. Francisco - Chief Financial Officer Gary S.

ORGO Sales Drop 23%